Lipidavit Sl

Phospholipids from soya beans, the active ingredient in Lipidavit Sl, is an excipient presented as an unspecified form for oral use. It provides emulsifying and solubilizing functions that support the stability and bioavailability of oral and parenteral drug products.

GNH USA supplies Lipidavit Sl as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lipidavit Sl, containing phospholipids from soya beans, is employed as an excipient to improve the performance of oral and parenteral medicines.

- Oral solid dosage forms: enhances emulsification and drug dissolution. - Injectable solutions: stabilises lipid‑based carriers and improves solubility. - Soft gelatin capsules: acts as a film‑forming agent to maintain capsule integrity.

Phospholipid excipients are generally well tolerated, but adverse reactions can occur, particularly in individuals with soy sensitivity.

Common Side Effects: - Mild gastrointestinal discomfort: transient nausea or abdominal bloating. - Transient flatulence: excess gas due to altered lipid digestion. - Mild headache: occasional short‑lived headache.

Serious or Rare Side Effects: - Anaphylactic reaction: severe hypersensitivity requiring immediate medical attention. - Angioedema: swelling of face, lips, or throat. - Severe urticaria: widespread hives with itching. - Respiratory distress: bronchospasm or wheezing in susceptible patients. - Hepatic enzyme elevation: rare increase in liver function tests.

When using Lipidavit Sl, consider patient‑specific factors and handling requirements.

- Allergy assessment: screen for soy or phospholipid hypersensitivity before use. - Monitor for hypersensitivity: observe patients for signs of allergic reaction during initial exposure. - Use in compromised liver function: exercise caution in patients with severe hepatic impairment. - Compatibility check: verify that the excipient does not adversely interact with the active pharmaceutical ingredient. - Storage: Store below 25°C: keep in the original container, protect from moisture and direct sunlight.

Phospholipid excipients may influence the absorption or stability of co‑administered drugs.

Major Interactions (Avoid): - Soy‑based drug products: concurrent use may increase risk of allergic reactions. - Highly lipophilic drugs: may cause unpredictable absorption spikes.

Moderate Interactions (Monitor Closely): - Anticoagulants: monitor INR as phospholipids can affect platelet function. - Immunosuppressants: observe for altered plasma levels. - Oral contraceptives: assess efficacy if formulation changes occur.